Mosaic ImmunoEngineering (CPMV) Net Income (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Net Income of -$175351.0 for Q1 2026, up 3.29% year-over-year from -$169762.5 in Q1 2025, and down 3.67% quarter-over-quarter from -$169137.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Net Income (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Net Income history runs 17 years deep, the most recent figure standing at -$175351.0 for Q1 2026.
- In Q1 2026, Net Income rose 3.29% year-over-year to -$175351.0; the TTM figure through Mar 2026 stood at -$681877.0 (up 16.31% YoY), while the FY2025 annual figure was -$687846.0, up 25.39% from the prior year.
- Net Income for Q1 2026 stood at -$175351.0, down from -$169137.0 in the prior quarter.
- The five-year high for Net Income was $19612.0 in Q2 2023, with the low at -$929632.0 in Q2 2022.
- The 5-year median for Net Income is -$186730.0 (2024), against an average of -$304369.7.
- The sharpest annual moves came in 2023 and 2024: Net Income surged 102.11% in 2023, then slumped 1597.64% in 2024.
- Mosaic ImmunoEngineering's Net Income stood at -$534102.0 in 2022, then surged by 44.66% to -$295558.0 in 2023, then surged by 48.22% to -$153044.0 in 2024, then fell by 10.52% to -$169137.0 in 2025, then declined by 3.67% to -$175351.0 in 2026.
- Business Quant data shows CPMV's Net Income at -$175351.0 in Q1 2026, -$169137.0 in Q4 2025, and -$165361.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | -175,351.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,351.00 |
| Dec 31, 2025 | -169,137.00 |
| Sep 30, 2025 | -165,361.00 |
| Jun 30, 2025 | -172,028.00 |
| Mar 31, 2025 | -181,320.00 |
| Dec 31, 2024 | -153,044.00 |
| Sep 30, 2024 | -186,730.00 |
| Jun 30, 2024 | -293,717.00 |
| Mar 31, 2024 | -288,492.00 |
| Dec 31, 2023 | -295,558.00 |
| Sep 30, 2023 | -333,246.00 |
| Jun 30, 2023 | 19,612.00 |
| Mar 31, 2023 | -399,043.00 |
| Dec 31, 2022 | -534,102.00 |
| Sep 30, 2022 | -153,652.00 |
| Jun 30, 2022 | -929,632.00 |
| Mar 31, 2022 | -763,484.00 |
| Dec 31, 2021 | -850,268.00 |
| Sep 30, 2021 | -1.05 Mn |
| Jun 30, 2021 | -979,424.00 |